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Introduction. The clinical course of Coronavirus Disease 2019 (COVID-19) is highly heterogenous, ranging from asymptomatic to
fatal forms. The identification of clinical and laboratory predictors of poor prognosis may assist clinicians in monitoring strategies
and therapeutic decisions. Materials and Methods. In this study, we retrospectively assessed the prognostic value of a simple tool,
the complete blood count, on a cohort of 664 patients (F 260; 39%, median age 70 (56-81) years) hospitalized for COVID-19 in
Northern Italy. We collected demographic data along with complete blood cell count; moreover, the outcome of the
hospital in-stay was recorded. Results. At data cut-off, 221/664 patients (33.3%) had died and 453/664 (66.7%) had been
discharged. Red cell distribution width (RDW) (χ2 10.4; p < 0:001), neutrophil-to-lymphocyte (NL) ratio (χ2 7.6; p = 0:006),
and platelet count (χ2 5.39; p = 0:02), along with age (χ2 87.6; p < 0:001) and gender (χ2 17.3; p < 0:001), accurately predicted
in-hospital mortality. Hemoglobin levels were not associated with mortality. We also identified the best cut-off for mortality
prediction: a NL ratio > 4:68 was characterized by an odds ratio for in-hospital mortality ðORÞ = 3:40 (2.40-4.82), while the OR
for a RDW> 13:7% was 4.09 (2.87-5.83); a platelet count > 166,000/μL was, conversely, protective (OR: 0.45 (0.32-0.63)).
Conclusion. Our findings arise the opportunity of stratifying COVID-19 severity according to simple lab parameters, which may
drive clinical decisions about monitoring and treatment.
1. Introduction
The global spread of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) generated a pandemic out-
break in late 2019-early 2020, which severely impacted on
care delivery worldwide. The clinical picture caused by the
abovementioned viral infection has been called Coronavirus
disease 2019 (COVID-19): its clinical manifestations encom-
pass a wide range of entities, from a mild flu-like illness to
life-threatening forms [1]. Despite differences among coun-
tries, the overall in-hospital mortality is high, being reported
up to 30% [2]. The reasons underlying such a different
clinical behavior are still unknown; thus, it is difficult to
predict who will develop a severe clinical picture and who,
conversely, will show a mild disease.
Thus, the identification of predictors of mortality might
be valuable to adjust clinicians’ approach to monitoring
and therapy. Among clinical parameters, proposed predic-
tors of poor prognosis include age, comorbidities, and male
gender [3, 4]. Moreover, some laboratory variables have been
associated to mortality in different cohorts [5, 6]; in a recent
meta-analysis, elevated cardiac troponin, C-reactive protein,
interleukin-6, D-dimer, creatinine, liver function tests and
decreased levels of albumin turned out to predict mortality
among COVID-19 hospitalized patients [7]. Furthermore,
preliminary reports suggest that blood cell count may be
particularly relevant [8, 9]. Blood cell count is a simple,
highly informative, and universally available exam. The
validation of these early reports may give to clinicians a
further valuable tool for clinical risk stratification. On
these grounds, here we aimed to verify whether simple
data retrievable from blood cell count may predict the out-
come in patients admitted to the hospital because of
COVID-19.
2. Methods
2.1. Study Population. The study was conducted at the
“Maggiore della Carità” University Hospital in Novara,
Northern Italy.
Scanning the hospital administrative database, we
retrieved all consecutive patients older than 18 years of age,
admitted to the hospital after emergency room evaluation,
with a confirmed diagnosis of SARS-CoV-2 infection by
reverse-transcriptase polymerase chain reaction (RT-PCR)
of a nasopharyngeal swab, between 1st March 2020 and 28th
April 2020. We identified a total of 763 patients.
We revised data available from central lab software to
retrieve the complete blood cell count at hospital admission,
along with gender and age. We also recorded the outcome of
in-hospital stay (discharged or deceased).
The study protocol was approved by the Institutional
Review Board (Comitato Etico Interaziendale Novara; IRB
code CE 97/20) and conducted in strict accordance with
the principles of the Declaration of Helsinki. Prospective
informed consent was waived by competent authorities
due to the retrospective nature of the study and the use
of pseudonymized data.
2.2. Statistical Analysis. Data were summarized according to
groups as median and (25th-75th percentile) and analyzed
using the Wilcoxon test. Categorical variables, whenever
dichotomous or nominal, were reported as frequencies and
percentages and analyzed through the Chi-square test.
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The optimal cut-off value for each predictor has been
computed considering as criterion the sum of sensitivity
and specificity maximization [10]. The cut-off values have
been considered to dichotomize the predictors; the area
under curve (AUC) values in discriminating the in-hospital
mortality have been reported.
Univariate analysis and multivariate logistic regression
were carried out to quantify the effects of the dichotomized
covariates on in-hospital mortality. We included in the mul-
tivariate models the following covariates: age, gender, and
laboratory parameters derived from complete blood count.
The .632 bootstrap (1000 resamples) validation proce-
dure was carried out to evaluate the predictive logistic regres-
sion model performance reporting the Harrell-C statistics
corrected for overoptimism [11].
The p values have been adjusted via Holm multiple
testing procedure.
Statistical analyses were conducted using R 3.5.2 with the
rms packages [12]. The threshold of statistical significance
was 0.05 for all tests used (two tailed).
3. Results
At data cut-off, 664 (260 females, 39%; median age 70 (56-81)
years) patients completed their hospital in-stay: 221/664
patients (33.3%) had died and 453/664 (66.7%) had been dis-
charged. The median time to death was 6 days [2–10], while
the median time to discharge was 8 days [5–14] (p < 0:001).
Table 1 reports the main features of the study population.
The proportion of males was higher among those who died
in-hospital; moreover, the age was significantly higher in this
group of subjects, who also showed increased white blood
cells (WBC), absolute neutrophil count (ANC), neutrophil-
to-lymphocyte ratio (NL ratio), eosinophil count, mean
corpuscular hemoglobin (MCH), mean corpuscular volume
(MCV), and red cell distribution width (RDW). Conversely,
survivors had significantly higher platelet count, hemoglobin
concentration, and absolute lymphocyte count (ALC).
We ran a first multivariate model to test the predictive
role of all the parameters derived from complete blood count.
The results are shown in Table 2. Along with age and gender,
RDW was the strongest independent predictor of mortality;
ANC was still significantly and independently predictive of
in-hospital mortality, while the contribution given by WBC,
ALC, and platelet count was weaker. Predictably, the effect
of NL ratio was blunted by the inclusion of ANC and ALC
into the model.
On the basis of the first model, we ran a further multi-
variate analysis, including age, gender, platelet count, NL
ratio (used as a summary measure for white blood cell count
and differential), RDW, and hemoglobin. RDW (χ2 10.40;
p < 0:001), NL ratio (χ2 7.59; p = 0:006), and platelet count
(χ2 5.39; p = 0:02), along with age (χ2 87.6; p < 0:001) and
gender (χ2 17.3; p < 0:001, confirmed their independent
Table 1: Clinical features of the study population. The main general features of the study population are reported. Categorical variables,
whenever dichotomous or nominal, were reported as frequencies and percentages and analyzed through the Chi-square test.
Total (N 664) Discharged (N 453) Dead (N 211) p
Age (years) 70 (56-81) 63 (52-75) 80 (73-87) <0.0001
Gender (M/F) 404 (61)/260 (39) 260 (57)/193 (43) 144 (68)/67 (32) 0.008
WBC (×103/μL) 7.3 (5.2-10.9) 6.8 (5.1-9.7) 8.4 (5.8-12.0) <0.0001
Neutrophils (×103/μL) 5.3 (3.5-8.6) 4.8 (3.4-7.6) 6.7 (4.1-9.6) <0.0001
Lymphocytes (×103/μL) 1.07 (0.76-1.54) 1.15 (0.82-1.56) 0.92 (0.66-1.92) <0.0001
Eosinophils (×103/μL) 0.01 (0.00-0.03) 0.01 (0.00-0.04) 0.00 (0.00-0.01) <0.0001
NL ratio 4.7 (2.8-9.1) 4.0 (2.5-7.0) 7.0 (3.8-13.2) <0.0001
Platelets (×103/μL) 195 (149-249) 198 (157-250) 168 (129-243) <0.0001
Hb (gr/dL) 13.4 (11.8-14.7) 13.7 (12.1-14.8) 12.9 (11.4-14.4) 0.08
MCH (pg) 29.5 (28.2-30.7) 29.3 (28.3-30.5) 29.8 (28.0-31.1) 0.04
MCV (fL) 89.5 (85.7-93.4) 88.8 (85.1-91.9) 91.3 (86.9-94.6) <0.0001
RDW (%) 13.7 (12.9-15.1) 13.3 (12.7-14.4) 14.5 (13.5-15.9) <0.0001
Comparison between survivors and dead has been performed by a nonparametricWilcoxon test. For abbreviation: M: males; F: females;WBC: white blood cells;
NL ratio: neutrophil-to-lymphocyte ratio; MCH: mean cell hemoglobin; MCV: mean corpuscular volume; RDW: red cell distribution width.
Table 2: Multivariable model. The table shows a multivariable
model including all blood count-derived variables.
χ2 p
Age (years) 77.04 <0.0001
Gender (M/F) 17.3 <0.0001
WBC (×103/μL) 3.63 0.06
Neutrophils (×103/μL) 4.25 0.04
Lymphocytes (×103/μL) 3.78 0.05
Eosinophils (×103/μL) 1.71 0.19
NL ratio 0.48 0.49
Platelets (×103/μL) 3.74 0.05
Hb (gr/dL) 0.37 0.54
MCH (pg) 0.56 0.45
MCV (fL) 0.32 0.57
RDW (%) 12.74 <0.0001
For abbreviation: M: males; F: females; WBC: white blood cells; NL ratio:
neutrophil-to-lymphocyte ratio; MCH: mean cell hemoglobin; MCV: mean
corpuscular volume; RDW: red cell distribution width.
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predictive role. Conversely, hemoglobin (χ2 2.28; p = 0:131)
was not associated with outcome.
We further tried to identify the best performing cut-off
for these parameters; in Table 3, we reported our results, with
the respective area under the curve (AUC) and odds ratio.
On these bases, we built a final multivariate model which
confirmed that age > 74 years (χ2 67.1; p < 0:001), male gen-
der (χ2 14.9; p < 0:001), platelets < 166,000 (χ2 22.3; p <
0:0001), NL ratio > 4:68 (χ2 21.4; p < 0:0001), and RDW>
13:7% (χ2 25.2; p < 0:001) were independent predictors of
in-hospital mortality. Once again, hemoglobin (χ2 0.03; p =
0:85) was not associated to in-hospital mortality.
4. Discussion
In the present paper, we investigated a cohort of hospitalized
patients in Northern Italy with a defined diagnosis of
COVID-19, showing that simple complete blood count
parameters obtained at hospital admission accurately predict
in-hospital mortality. A first finding deserving a comment is
the observed mortality which, in our cohort, was very high.
More than 30% of patients died during hospital stay. This
is in line with previous observations from other groups
[13–15], although data about in-hospital mortality widely
vary, with case fatality rates much lower in the first reported
cohorts from China [16, 17]. The reasons of this discrepancy
are still largely unknown; however, both the phase of the epi-
demic curve and the geographic region have an impact in
determining a very different prognosis in COVID-19
patients. Our study is adequately powered to compensate
for variations in the mortality rate: for example, with a NL
ratio above 7 in 25% of discharged patients and 50% of
deceased patients, the estimated power is 0.9999 for at a mor-
tality rate of 0.33 (33%) and remains >0.80 for all populations
with mortality rate above 0.06 (6%).Thus, our data strongly
support the idea that complete blood count, a routine test
for most patients admitted to hospital, might be highly infor-
mative with regard to prognosis of COVID-19 patients
admitted to hospital. This is in line with different studies
reporting a potential role for blood count in the prediction
of mortality in the context of Emergency Medicine, cardio-
vascular and cerebrovascular diseases [18–21].
More specifically, we identified three main predictors of
in-hospital death: NL ratio, platelet count, and RDW.
NL ratio has already been described to be strongly associ-
ated with COVID-19 prognosis [22–24]. The ratio magnifies
the strength of the association of both components, neutro-
phil count and lymphocyte count, in predicting the outcome
for COVID-19 patients. Whether neutrophilia is just a bio-
marker of disease severity or has a pathogenetic role is
unclear. However it is worth mentioning that COVID-19
mortality seems to be frequently related to the development
of thromboembolic complications and systemic inflamma-
tion [25, 26]. Neutrophilia is a known marker of venous
thrombosis, possibly contributing by driving a necroinflam-
matory response [27]. Furthermore, neutrophils play their
protective role not only through phagocytosis but also
exploiting neutrophil extracellular trap (NET) formation
[28]. Although NETs are beneficial in the host defense
against pathogens, sustained NET formation may drive
collateral damage in different human conditions, including
viral infections [29]. It has been postulated that, in COVID-
19, the inappropriate NET production might be crucial in
the development of the “cytokine storm” responsible of acute
respiratory distress syndrome (ARDS), severe inflammatory
response syndrome (SIRS), and sepsis [27]. With respect to
lymphocytes, it has been suggested that SARS-CoV-2 infec-
tionmay primarily affect T lymphocytes [30] and that lympho-
penia in severe patients is mainly related to a decreased ALC,
especially CD8+ T cells [31]. Since T cells are important for
dampening overactive innate immune responses during viral
infection, their loss during SARS-CoV-2 infection may result
in a more severe inflammatory responses [32].
We suggest to use NL ratio, in this context, being its
prognostic value higher, as shown by our data. In fact, NL
ratio magnifies the predictive potential of neutrophilia and
lymphopenia, being 4.68 the best prognostic cut-off.
With respect to platelets, some authors suggested that
thrombocytopenia may be a negative prognostic factor. In a
recent meta-analysis on 31 studies including 7163 patients,
a lower platelet count predicted severe COVID-19 [33]; the
Table 3: Univariable analysis. The optimal cut-off value for each predictor has been reported together with AUC (area under the curve)
values. The univariable logistic regression OR (odds ratio) together with 95% confidence interval (CI) have been also reported.
Cut-off AUC OR (CI95%) p
Age (years) 74 0.786 6.90 (4.80-9.93) <0.0001
WBC (×103/μL) 8,360 0.587 1.98 (1.42-2.77) <0.0001
Neutrophils (×103/μL) 6,310 0.617 2.56 (1.83-3.59) <0.0001
Lymphocytes (×103/μL) 1,130 0.618 0.42 (0.30-0.60) <0.0001
Eosinophils (×103/μL) 0,100 0.587 0.57 (0.41-0.80) 0.0001
NL ratio 4.68 0.661 3.40 (2.40-4.82) <0.0001
Platelets (×103/μL) 166 0.582 0.45 (0.32-0.63) <0.0001
Hb (gr/dL) 13.0 0.577 0.60 (0.39-0.75) 0.0002
MCH (pg) 30.8 0.549 1.84 (1.26-2.68) 0.0001
MCV (fL) 90.6 0.602 2.51 (1.80-3.52) <0.0001
RDW (%) 13.7 0.689 4.09 (2.87-5.83) <0.0001
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mechanism by which SARS-CoV-2 leads to platelet con-
sumption, especially in case of severe disease, is unknown.
A possible explanation is that the lung damage might lead
to platelet activation and aggregation, finally causing throm-
bocytopenia [34]. A limitation of our study is that we did not
exclude patients affected by liver cirrhosis, which is tipically
associated to thrombocytopenia; this might have partially
biased our finding [35].
Finally, we demonstrated that RDW is a very strong pre-
dictor of mortality. According to our data, RDW is character-
ized by the highest χ2 and OR for in-hospital mortality among
all the variables considered. The clinical value of RDW is often
neglected; in the last few years, it has been recognized as a
common prognostic predictor in many human diseases: acute
kidney injury, cancer, acute pancreatitis, and respiratory fail-
ure [36–40]. The predictive significance of RDW in the con-
text of COVID-19 might reflect the effect on erythropoiesis
of respiratory failure and systemic inflammation [41, 42].
Our study has some limitations, due to the context in
which we were forced to act by the pandemic; in particular,
the observational nature of the study limited data availability
and did not allow us to correct for potential confounders.
Despite these limitations, our findings may raise the opportu-
nity of stratifying disease severity according to simple lab
parameters, which may drive clinical decisions about moni-
toring and treatment.
5. Conclusions
In the present study, we demonstrated that some simple
parameters derived from complete blood cell count have
prognostic implications in the course of COVID-19, being
able to identify those patients at higher risk of in-hospital
mortality. The confirmation of these preliminary observa-
tions may make available to clinicians novel useful tools for
prognostic stratification.
Data Availability
Data are available upon reasonable request to the corre-
sponding author.
Conflicts of Interest
The authors have no conflict of interest to declare.
Authors’ Contributions
PPS had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy
of the data analysis. MB, MP, GCA, and PPS conceptualized
and designed the study. AA, GA, PAV, RA, RA, GA, PEB,
GB, FB, EB, AB, MB, SB, MB, MB, SB, MB, MB, FB, PB,
LB, SB, MB, EC, EC, VC, RC, AC, AC, GFC, LMC, FC, GC,
EC, CC, MGC, CC, CC, EC, TD, PD, FDC, SDV, UD,
DDB, EE, ZF, DF, AF, IG, GG, AG, SG, PLG, CAG, MG,
MLG, FG, AG, GMG, IG, VGV, FG, LCG, CG, LG, II, MI,
MK, EL, ICL, RL, IL, VL, LL, AM, MM, GFM, MM, LM,
PM, MM, CM, UM, MM, IN, AN, CO, SAP, AP, AP, FP,
GP, AP, ARP, IP, LR, RR, CR, ER, AR, AR, LS, MS, MS, PS,
MS, AS, LS, ES, CS, VT, PAT, ST, RV, VV, DZ, EZ, PZ,
and FZ acquired the data. MB, DA, EH, GG, FBA, FF, MP,
and PPS analyzed and interpreted the data. MB made the
draft of the manuscript. All the authors critically revised the
manuscript for important intellectual content. DA, EH, and
PPS did the statistical analysis. EH, AC, and LS did the
administrative, technical, or material support. GP, MP,
GCA, and PPS supervised study.
Acknowledgments
We would like to thank for their massive contribution to
clinical data collection all the COVID UPO Clinical Team:
Giuseppe Aiosa,4 Andrea Airoldi,2 Ambra Barco,2 Olivia
Bargiacchi,2 Simona Bazzano,2 Paola Berni,2 Bianca Bianchi,2
Sara Bianco,2 Stefano Biffi,2 Valeria Binda,2 Tatiana Bolgeo,4
Cesare Bolla,4 Valeria Bonato,4 Giacomo Bonizzoni,4 Alice
Bragantini,4 Diego Brustia,2 Valentina Bullara,2 Michela
Burlone,2 Fabio Brustia,2 Stefano Caccia,2 Anna Calareso,3
Gianmaria Cammarota,2 Laura Cancelliere,2 Roberto
Carbone,4 Antonella Cassinari,4 Elisa Ceriani,2 Tiziana
Cena,2 Elisa Clivati,2 Laura Collimedaglia3, Andrea Colom-
batto,2 Cristina Cornella,2 Martina Costanzo,1,2 Alessandro
Croce,1,2 Carla De Benedittis,1,2 Stefania Delorenzi,4 Rosa
Dionisio,4 Paolo Donato,2 Maria Esposito,2 Stefano Fangazio,2
Alessandro Feggi,2 Sara Ferrillo,4 Valentina Foci,3 Gian Paolo
Fra,2 Claudio Gaggino,4 Eleonora Gambaro,2 Eleonora
Gattoni,2 Luca Gattoni,2 Fabio Giacchero,4 Romina
Gianfreda,4 Ailia Giubertoni,2 Lorenzo Grecu,4 Francesca
Grossi,2 Gabriele Guglielmetti,2 Stefania Guido,2 Giacomo
Iannantuoni,2 Susanna Ingrao,2 Amalia Jona,2 2 Elisa
Lazzarich,2 Raffaella Lissandrin,4 Elisabetta Maduli,2
Federica Magnè,4 Eugenio Mantia,4 Debora Marangon,2
Maurilio Massara,2 Erica Matino,2 Maria Grazia Mauri,2
Mirta Menegatti,2 Roberta Moglia,2 Rossella Molinari,2
Stefania Morelli,2 Paola Morlino,2 Paola Naldi,2 Claudio
Nebbiolo,2 Pinuccia Omodeo,4 Daniela Palmieri,2 Antonio
Panero,2 Massimiliano Parodi,4 Roberta Pedrazzoli,2
Carolina Pelazza,4 Serena Penpa,4 Raffaella Perucca,2 Alice
Pirovano,1,2 Sergio Pittau,2 Patrizia Pochetti,3 Federica
Poletti,2 Biagio Polla,4 Paolo Prandi,2 Flavia Prodam,1,2
Pierluigi Prosperini,2 Alessia Puma,2 Marco Quaglia,2
Alberto Raie,3 Rachele Rapetti,2 Silvia Ravera,4 Azzurra
Re,2 Matia Reale,4 Antonella Rossati,2 Maura Rossi,4 Paola
Rossi,4 Roberto Rostagno,2 Annalisa Roveta, MD4 Giulia
Salomoni,4 Maria Teresa Samà,2 Eleonora Sarchi,4 Maddalena
Sarcoli,2 Cristina Sarda,4 Ilaria Sguazzotti,2 Daniele Soddu,1,2
Daniele Sola,2 Paolo Stobbione,4 Monica Todoerti,4 Gian
Carlo Vallese,2 Claudia Varrasi,2 Alessia Veia,2 Gian Luca
Vignazia,2 Isabella Zanotti,2 Erika Zecca,1,2 Daniela Zichittella,4
Giuliana Zisa,2 Elisabetta Zoppis.2
References
[1] N. Chen, M. Zhou, X. Dong et al., “Epidemiological and
clinical characteristics of 99 cases of 2019 novel coronavirus
pneumonia inWuhan, China: a descriptive study,” The Lancet,
vol. 395, no. 10223, pp. 507–513, 2020.
5Disease Markers
[2] A. B. Docherty, E. M. Harrison, C. A. Green et al., “Features of
20 133 UK patients in hospital with covid-19 using the ISARIC
WHO clinical characterisation protocol: prospective observa-
tional cohort study,” BMJ, vol. 369, article m1985, 2020.
[3] J. B. Galloway, S. Norton, R. D. Barker et al., “A clinical risk
score to identify patients with COVID-19 at high risk of criti-
cal care admission or death: an observational cohort study,”
The Journal of Infection, vol. 81, pp. 282–288, 2020.
[4] Z. Imam, F. Odish, I. Gill et al., “Older age and comorbidity are
independent mortality predictors in a large cohort of 1305
COVID-19 patients in Michigan, United States,” Journal of
Internal Medicine, vol. 288, no. 4, pp. 469–476, 2020.
[5] S. Piano, A. Dalbeni, E. Vettore et al., “Abnormal liver function
tests predict transfer to intensive care unit and death in COVID-
19,” Liver International, vol. 40, no. 10, pp. 2394–2406, 2020.
[6] R. Herlekar, A. S. Roy, andM.Matson, “Hypoalbuminaemia in
COVID-19 infection: a predictor of severity or a potential
therapeutic target?,” Journal of Medical Virology, vol. 93,
no. 1, pp. 83-84, 2020.
[7] W. Tian, W. Jiang, J. Yao et al., “Predictors of mortality in hos-
pitalized COVID-19 patients: a systematic review and meta-
analysis,” Journal of Medical Virology, vol. 92, no. 10,
pp. 1875–1883, 2020.
[8] H. Sun, R. Ning, Y. Tao et al., “Risk factors for mortality in 244
older adults with COVID-19 in Wuhan, China: a retrospective
study,” Journal of the American Geriatrics Society, vol. 68,
no. 6, pp. E19–E23, 2020.
[9] X. Yan, F. Li, X. Wang et al., “Neutrophil to lymphocyte
ratio as prognostic and predictive factor in patients with
coronavirus disease 2019: a retrospective cross-sectional
study,” Journal of Medical Virology, vol. 92, no. 11,
pp. 2573–2581, 2020.
[10] X. Robin, N. Turck, A. Hainard et al., “pROC: an open-source
package for R and S+ to analyze and compare ROC curves,”
BMC Bioinformatics, vol. 12, no. 1, p. 77, 2011.
[11] H. FEJ, “rms: regression modeling strategies. R package ver-
sion 4.1-3,” 2014, http://CRAN.R-project.org/package=rms.
[12] R Core Team, R: A Language and Environment for Statistical
Computing, R Foundation for Statistical Computing, Vienna,
Austria, 2019, https://www.R-project.org.
[13] F. Zhou, T. Yu, R. Du et al., “Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study,” The Lancet, vol. 395,
no. 10229, p. 1038, 2020.
[14] G. Grasselli, A. Zangrillo, A. Zanella et al., “Baseline character-
istics and outcomes of 1591 patients infected with SARS-CoV-
2 admitted to ICUs of the Lombardy region, Italy,” JAMA,
vol. 323, no. 16, pp. 1574–1581, 2020.
[15] S. Richardson, J. S. Hirsch, M. Narasimhan et al., “Presenting
characteristics, comorbidities, and outcomes among 5700
patients hospitalized with COVID-19 in the New York City
area,” Journal of the American Medical Association, vol. 323,
no. 20, pp. 2052–2059, 2020.
[16] R. Chen, W. Liang, M. Jiang et al., “Risk factors of fatal
outcome in hospitalized subjects with coronavirus disease
2019 from a nationwide analysis in China,” Chest, vol. 158,
no. 1, pp. 97–105, 2020.
[17] X.-Y. Zhao, X.-X. Xu, H.-S. Yin et al., “Clinical characteristics
of patients with 2019 coronavirus disease in a non-Wuhan
area of Hubei Province, China: a retrospective study,” BMC
Infectious Diseases, vol. 20, no. 1, p. 311, 2020.
[18] K. Brzeźniakiewicz-Janus, M. D. Lancé, A. Tukiendorf et al.,
“Selected hematological biomarkers to predict acute mortality
in emergency department patients. Recent Polish hospital
statistics,” Disease Markers, vol. 2020, Article ID 8874361, 10
pages, 2020.
[19] L. Yan and Z. D. Hu, “Red blood cell distribution width,
neutrophil-to-lymphocyte ratio, and in- hospital mortality in
dyspneic patients admitted to the emergency department,”
Disease Markers, vol. 2020, Article ID 8839506, 5 pages, 2020.
[20] J. Budzianowski, K. Pieszko, P. Burchardt, J. Rzeźniczak, and
J. Hiczkiewicz, “The role of hematological indices in patients
with acute coronary syndrome,” Disease Markers, vol. 2017,
Article ID 3041565, 9 pages, 2017.
[21] N. Li, H. Zhou, and Q. Tang, “Red blood cell distribution
width: a novel predictive indicator for cardiovascular and cere-
brovascular diseases,” Disease Markers, vol. 2017, Article ID
7089493, 23 pages, 2017.
[22] A. P. Yang, J. P. Liu, W. Q. Tao, and H. M. Li, “The diagnostic
and predictive role of NLR, d-NLR and PLR in COVID-19
patients,” International Immunopharmacology, vol. 84, article
106504, 2020.
[23] S. Sun, X. Cai, H. Wang et al., “Abnormalities of peripheral
blood system in patients with COVID-19 in Wenzhou,
China,” Clinica Chimica Acta, vol. 507, pp. 174–180, 2020.
[24] F. Zeng, L. Li, J. Zeng et al., “Can we predict the severity of
coronavirus disease 2019 with a routine blood test?,” Polish
Archives of Internal Medicine, vol. 130, no. 5, pp. 400–406,
2020.
[25] D. McGonagle, K. Sharif, A. O’Regan, and C. Bridgewood,
“The role of cytokines including interleukin-6 in COVID-19
induced pneumonia and macrophage activation syndrome-
like disease,” Autoimmunity Reviews, vol. 19, no. 6, article
102537, 2020.
[26] N. Tang, H. Bai, X. Chen, J. Gong, D. Li, and Z. Sun, “Antico-
agulant treatment is associated with decreased mortality in
severe coronavirus disease 2019 patients with coagulopathy,”
Journal of Thrombosis and Haemostasis, vol. 18, no. 5,
pp. 1094–1099, 2020.
[27] B. Tomar, H. J. Anders, J. Desai, and S. R. Mulay, “Neutrophils
and neutrophil extracellular traps drive necroinflammation in
COVID-19,” Cell, vol. 9, no. 6, article E1383, 2020.
[28] T. Németh, M. Sperandio, and A. Mócsai, “Neutrophils as
emerging therapeutic targets,” Nature Reviews. Drug Discov-
ery, vol. 19, no. 4, pp. 253–275, 2020.
[29] G. Schönrich and M. J. Raftery, “Neutrophil extracellular traps
go viral,” Frontiers in Immunology, vol. 7, p. 366, 2016.
[30] G. Chen,W. G. DiWu, Y. Cao et al., “Clinical and immunolog-
ical features of severe and moderate coronavirus disease 2019,”
The Journal of Clinical Investigation, vol. 130, no. 5, pp. 2620–
2629, 2020.
[31] J. Liu, S. Li, J. Liu et al., “Longitudinal characteristics of
lymphocyte responses and cytokine profiles in the peripheral
blood of SARS-CoV-2 infected patients,” eBioMedicine,
vol. 55, article 102763, 2020.
[32] K. D. Kim, J. Zhao, and S. Auh, “Adaptive immune cells tem-
per initial innate responses,” Nature Medicine, vol. 13, no. 10,
pp. 1248–1252, 2007.
[33] S. Q. Jiang, Q. F. Huang, W. M. Xie, C. Lv, and X. Q. Quan,
“The association between severe COVID-19 and low platelet
count: evidence from 31 observational studies involving 7613
participants,” British Journal of Haematology, vol. 190, 2020.
6 Disease Markers
[34] J. Yang, M. Yang, F. Xu et al., “Effects of oxygen-induced lung
damage on megakaryocytopoiesis and platelet homeostasis in
a rat model,” Pediatric Research, vol. 54, no. 3, pp. 344–352,
2003.
[35] T. M. Alempijevic, M. S. Lalosevic, I. Dumic et al., “Diagnostic
accuracy of platelet count and platelet indices in noninvasive
assessment of fibrosis in nonalcoholic fatty liver disease
patients,” Canadian Journal of Gastroenterology &Hepatology,
vol. 2017, article 6070135, 5 pages, 2017.
[36] F. X. Zhang, Z. L. Li, Z. D. Zhang, and X. C. Ma, “Prognostic
value of red blood cell distribution width for severe acute pan-
creatitis,” World Journal of Gastroenterology, vol. 25, no. 32,
pp. 4739–4748, 2019.
[37] X. S. Yu, Z. Q. Chen, Y. F. Hu et al., “Red blood cell distribu-
tion width is associated with mortality risk in patients with
acute respiratory distress syndrome based on the Berlin defini-
tion: a propensity score matched cohort study,” Heart Lung,
vol. 49, pp. 641–645, 2020.
[38] B. Wang, H. Lu, Y. Gong, B. Ying, and B. Cheng, “The associ-
ation between red blood cell distribution width and mortality
in critically ill patients with acute kidney injury,” BioMed
Research International, vol. 2018, Article ID 9658216, 7 pages,
2018.
[39] J. Li, X. Yang, J. Ma, F. Gong, and Q. Chen, “Relationship of
red blood cell distribution width with cancer mortality in hos-
pital,” BioMed Research International, vol. 2018, Article ID
8914617, 8 pages, 2018.
[40] J. Howell, D. J. Pinato, R. Ramaswami et al., “Integration of the
cancer-related inflammatory response as a stratifying bio-
marker of survival in hepatocellular carcinoma treated with
sorafenib,” Oncotarget, vol. 8, no. 22, pp. 36161–36170, 2017.
[41] M. Bellan, D. Soddu, E. Zecca et al., “Association between red
cell distribution width and response to methotrexate in rheu-
matoid arthritis,” Reumatismo, vol. 72, no. 1, pp. 16–20, 2020.
[42] M. Bellan, A. Giubertoni, C. Piccinino et al., “Red cell distribu-
tion width and platelet count as biomarkers of pulmonary
arterial hypertension in patients with connective tissue disor-
ders,” Disease Markers, vol. 2019, Article ID 4981982, 7 pages,
2019.
7Disease Markers
